{"id":"https://openalex.org/W4362546207","doi":"https://doi.org/10.1158/2326-6066.c.6548972.v1","title":"Data from PD-L1 Mediates Dysfunction in Activated PD-1+ NK Cells in Head and Neck Cancer Patients","display_name":"Data from PD-L1 Mediates Dysfunction in Activated PD-1+ NK Cells in Head and Neck Cancer Patients","publication_year":2023,"publication_date":"2023-04-03","ids":{"openalex":"https://openalex.org/W4362546207","doi":"https://doi.org/10.1158/2326-6066.c.6548972.v1"},"language":"en","primary_location":{"id":"doi:10.1158/2326-6066.c.6548972.v1","doi":"https://doi.org/10.1158/2326-6066.c.6548972.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/2326-6066.c.6548972.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"http://dx.doi.org/10.1158/2326-6066.c.6548972.v1","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5071719413","display_name":"Fernando Concha\u2010Benavente","orcid":"https://orcid.org/0000-0002-3079-1996","observed_orcids":["https://orcid.org/0000-0002-3079-1996"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Fernando Concha-Benavente","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051498795","display_name":"Benjamin Kansy","orcid":"https://orcid.org/0000-0001-5934-5618","observed_orcids":["https://orcid.org/0000-0001-5934-5618"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Benjamin Kansy","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057924190","display_name":"Jessica M. Moskovitz","orcid":"https://orcid.org/0000-0003-2360-6411","observed_orcids":["https://orcid.org/0000-0003-2360-6411"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jessica Moskovitz","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065065876","display_name":"Jennifer D. Moy","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jennifer Moy","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004781857","display_name":"Uma R. Chandran","orcid":"https://orcid.org/0000-0002-0817-9880","observed_orcids":["https://orcid.org/0000-0002-0817-9880"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Uma Chandran","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5086074491","display_name":"Robert Louis Ferris","orcid":"https://orcid.org/0000-0001-6605-2071","observed_orcids":["https://orcid.org/0000-0001-6605-2071"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Robert L. Ferris","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11020","display_name":"Immune Cell Function and Interaction","score":0.6890000104904175,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11020","display_name":"Immune Cell Function and Interaction","score":0.6890000104904175,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.3100999891757965,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10307","display_name":"Head and Neck Cancer Studies","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2733","display_name":"Otorhinolaryngology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pd-1","display_name":"PD-1","score":0.8769999742507935},{"id":"https://openalex.org/keywords/pd-l1","display_name":"PD-L1","score":0.9990000128746033},{"id":"https://openalex.org/keywords/natural-killer-cells","display_name":"natural killer cells","score":0.9150000214576721},{"id":"https://openalex.org/keywords/head-and-neck-cancer","display_name":"head and neck cancer","score":0.9940000176429749},{"id":"https://openalex.org/keywords/cetuximab","display_name":"cetuximab","score":0.8999999761581421},{"id":"https://openalex.org/keywords/immune-checkpoint-blockade","display_name":"immune checkpoint blockade","score":0.8659999966621399},{"id":"https://openalex.org/keywords/tumor-microenvironment","display_name":"tumor microenvironment","score":0.859000027179718},{"id":"https://openalex.org/keywords/nk-cell-activation","display_name":"NK cell activation","score":0.8259999752044678},{"id":"https://openalex.org/keywords/nk-cell-dysfunction","display_name":"NK cell dysfunction","score":0.5950000286102295},{"id":"https://openalex.org/keywords/immune-evasion","display_name":"immune evasion","score":0.6069999933242798},{"id":"https://openalex.org/keywords/epidermal-growth-factor-receptor","display_name":"epidermal growth factor receptor","score":0.8029999732971191},{"id":"https://openalex.org/keywords/antibody-dependent-cellular-cytotoxicity","display_name":"antibody-dependent cellular cytotoxicity","score":0.8149999976158142},{"id":"https://openalex.org/keywords/neoadjuvant-therapy","display_name":"neoadjuvant therapy","score":0.8059999942779541}],"concepts":[{"id":"https://openalex.org/C2779998722","wikidata":"https://www.wikidata.org/wiki/Q420296","display_name":"Cetuximab","level":4,"score":0.8791089057922363},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5614282488822937},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.4644266366958618},{"id":"https://openalex.org/C2776107976","wikidata":"https://www.wikidata.org/wiki/Q1786433","display_name":"Tumor microenvironment","level":3,"score":0.43997105956077576},{"id":"https://openalex.org/C2781053074","wikidata":"https://www.wikidata.org/wiki/Q21100639","display_name":"PD-L1","level":4,"score":0.4201188087463379},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.41924503445625305},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.38209283351898193},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.38186657428741455},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.3614121079444885},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3353852927684784},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.3350070118904114}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/2326-6066.c.6548972.v1","doi":"https://doi.org/10.1158/2326-6066.c.6548972.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/2326-6066.c.6548972.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/2326-6066.c.6548972.v1","doi":"https://doi.org/10.1158/2326-6066.c.6548972.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/2326-6066.c.6548972.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2895397475","https://openalex.org/W3043004227","https://openalex.org/W3043536929","https://openalex.org/W2200370351","https://openalex.org/W1969104227","https://openalex.org/W4313386052","https://openalex.org/W3017311960","https://openalex.org/W2607191617","https://openalex.org/W4379984109","https://openalex.org/W2402061645"],"abstract_inverted_index":{"Abstract":[0],"Inhibitory":[1],"immune-checkpoint":[2],"receptors":[3],"(ICRs),":[4],"including":[5,29,41],"programmed":[6,128],"death":[7,129],"1":[8],"(PD-1),":[9],"have":[10],"been":[11],"characterized":[12],"as":[13],"exhaustion":[14],"markers":[15],"on":[16,43,115,161],"T":[17],"cells":[18,47,52,57,65,117,140,148,163,184],"that":[19,58,111],"infiltrate":[20],"the":[21,101,152,210],"tumor":[22],"microenvironment":[23],"(TME)":[24],"of":[25,39,80,113,181,222],"many":[26],"cancer":[27,33],"types,":[28],"head":[30],"and":[31,37,103,146,197],"neck":[32],"(HNC).":[34],"However,":[35],"expression":[36,112,160,228],"function":[38],"ICRs,":[40],"PD-1,":[42],"natural":[44],"killer":[45],"(NK)":[46],"remains":[48],"less":[49],"defined.":[50],"NK":[51,97,116,139,155,162,183,194,234],"are":[53,149],"innate":[54],"immune":[55,220],"effector":[56],"lyse":[59],"epidermal":[60],"growth":[61],"factor":[62],"receptor\u2013overexpressing":[63],"HNC":[64,132,202,223],"via":[66],"cetuximab-mediated":[67,193],"antibody-dependent":[68],"cytotoxicity.":[69],"Cetuximab":[70],"is":[71,84],"clinically":[72],"effective":[73],"but":[74,199],"only":[75,125,200],"in":[76,100,151,164,169,171],"10%":[77],"to":[78,86,218],"15%":[79],"patients.":[81],"Therefore,":[82,208],"it":[83],"necessary":[85],"investigate":[87],"how":[88],"immunomodulation":[89],"with":[90,142,204,225],"cetuximab":[91,175,230],"or":[92],"PD-1":[93,114,159,190],"blockade":[94,191],"might":[95],"enhance":[96],"cell":[98,156,195,235],"responses":[99],"TME":[102],"improve":[104],"monoclonal":[105],"antibody":[106],"therapeutic":[107],"efficacy.":[108],"We":[109],"observed":[110],"marks":[118],"an":[119],"activated":[120],"phenotype,":[121],"which":[122,166],"was":[123,167],"suppressed":[124],"after":[126],"binding":[127],"ligand-1":[130],"(PD-L1).":[131],"patients":[133],"who":[134],"exhibit":[135],"higher":[136],"circulating":[137],"PD-1+":[138,182],"associate":[141],"better":[143],"clinical":[144],"outcome,":[145],"these":[147],"enriched":[150],"TME.":[153],"Cetuximab-mediated":[154],"activation":[157,187,196],"increased":[158,192],"vitro,":[165],"confirmed":[168],"vivo":[170],"a":[172,215],"prospective":[173],"neoadjuvant":[174],"trial.":[176],"In":[177],"contrast,":[178],"PD-L1":[179,206,227],"ligation":[180],"diminished":[185],"their":[186],"status,":[188],"whereas":[189],"cytotoxicity,":[198],"against":[201],"targets":[203],"high":[205,226],"expression.":[207],"blocking":[209],"PD-1\u2013PD-L1":[211],"axis":[212],"may":[213],"be":[214],"useful":[216],"strategy":[217],"reverse":[219],"evasion":[221],"tumors":[224],"during":[229],"therapy":[231],"by":[232],"reversing":[233],"dysfunction.":[236]},"counts_by_year":[],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2023-04-06T00:00:00"}